Avoro Capital Advisors 13F: Exits MLTX Stake

Avoro Capital Advisors has completely exited its position in MoonLake Immunotherapeutics (NasdaqCM: MLTX), selling all 2 million shares it held. This move was revealed in the firm's latest 13F filing with the SEC, which reflects holdings as of the end of the reporting period.

What Changed in Avoro Capital Advisors' MoonLake Immunotherapeutics Position

Avoro Capital Advisors completely sold its stake in MoonLake Immunotherapeutics, offloading 2 million shares. This marks a 100% reduction from its previous holdings, leaving it with no shares in the company.

Other Institutional Activity in MoonLake Immunotherapeutics

Several other institutional investors have been active in MoonLake Immunotherapeutics. BVF Inc/IL reduced its holdings by 3.75 million shares, ending with 16,001,284 shares valued at approximately $298.26 million. Deep Track Capital, LP, however, increased its position by 1,798,792 shares, bringing its total to 6,408,863 shares worth about $119.46 million. Cormorant Asset Management, LP added 125,000 shares, resulting in a total of 4,480,433 shares valued at $83.52 million. Janus Henderson Group PLC also boosted its stake by 1,355,640 shares, ending with 3,451,628 shares valued at $64.30 million.

MoonLake Immunotherapeutics Stock Up 60.7%

Shares of MoonLake Immunotherapeutics (NasdaqCM: MLTX) traded at around $18.69. The company has a market capitalization of approximately $1.38 billion. As it is not currently profitable, there is no meaningful P/E ratio. The stock's 52-week range has been between $5.95 and $62.75, with a 50-day moving average of $17.76 and a 200-day moving average of $19.56. MoonLake's beta is 1.036, indicating moderate volatility compared to the market.

Insider Buying and Selling at MoonLake Immunotherapeutics

Recent insider activity at MoonLake Immunotherapeutics has shown several sales. Matthias Bodenstedt, the Chief Financial Officer, sold shares on multiple occasions under planned transactions, including 13,653 shares at $20.02 on May 11, 2026. CEO Jorge Santos da Silva also sold shares, including 51,873 shares at $18.23 on April 13, 2026, in an unplanned transaction.

Analysts Set New Price Targets

Analysts continue to show interest in MoonLake Immunotherapeutics. On May 12, 2026, Needham maintained a 'buy' rating with a target price of $30. HC Wainwright & Co. also maintained a 'buy' rating, setting a target price of $45 on May 11. Wolfe Research upgraded the stock to 'buy' with a $24 target on March 23. The consensus recommendation is a 'buy', with a mean target price of $27.62 based on 13 analyst opinions.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing treatments for inflammatory skin and joint diseases. Its lead product, Sonelokimab, is a tri-specific Nanobody targeting IL-17A and IL-17F for conditions like hidradenitis suppurativa and psoriatic arthritis. Founded in 2021, the company is headquartered in Zug, Switzerland, and led by CEO Dr. Jorge Santos da Silva.

Bottom Line

Avoro Capital Advisors' complete exit from MoonLake Immunotherapeutics is a notable move among institutional investors. As a clinical-stage biotech firm, MoonLake is closely watched for its innovative therapies targeting inflammatory diseases. This 13F filing provides a snapshot of past holdings and may not reflect current positions, but it offers insight into institutional sentiment.